Bayer submits Eylea for new indication in Japan
FRANKFURT Nov 28 (Reuters) - Bayer has submitted its Eylea eye medication, co-developed with Regeneron, for approval in Japan to treat Myopic Choroidal Neovascularization (myopic CNV), a cause of blindness.
In Japan, pathologic myopia and the associated myopic CNV is one of the most common causes of blindness, Bayer said.
Eylea, which also treats age-related macular degeneration (AMD) - the most common cause of blindness in the elderly - has been grabbing market share from rivals such as Roche AG's Lucentis since its launch in late 2011.
- Islamic State executes soldiers, takes hostages at Syria base: social media |
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |
- Gaza truce holding but Israel's Netanyahu under fire at home |
- WHO shuts Sierra Leone lab after worker infected with Ebola
- Ukraine warns Europe of Russian gas cut-off, Moscow denies